A novel combinatory treatment against a CDDP-resistant non-small cell lung cancer based on a Ruthenium(II)-cyclopentadienyl compound

The therapeutic approach to many solid tumors, including non-small cell lung cancer (NSCLC), is mainly based on the use of platinum-containing anticancer agents and is often characterized by acquired or intrinsic resistance to the drug. Therefore, the search for safer and more effective drugs is sti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Iris C. Salaroglio, Denitsa Stefanova, Ricardo G. Teixeira, Nuno F.B. Oliveira, Amer Ahmed, Fabio Fusi, Virginia Tzankova, Yordan Yordanov, Miguel Machuqueiro, Simona Saponara, Andreia Valente, Chiara Riganti
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-10-01
coleção:	Pharmacological Research
Assuntos:	Cisplatin resistance ruthenium-cyclopentadienyl non-small cell lung cancer biocompatibility cardiovascular toxicity
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1043661824002986
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!